Articles related to DIGITAL THERAPEUTICS (DTx)

The FDA-approved Rejoyn app, designed for major depressive disorder, combines therapeutic exercises and emotional regulation training to complement antidepressant therapy, showing significant improvement in clinical trials.

Rejoyn represents a significant advancement in the treatment of major depressive disorder, requiring prescription use and integrating brain-training exercises developed by leading mental health experts.

Explore the potential of Rejoyn™, a digital therapeutic now cleared by the FDA, which has shown to significantly reduce depressive symptoms in adults as an adjunct to traditional outpatient care, without any reported adverse events.

Better Therapeutics’ digital therapeutic app has been recognized with FDA breakthrough device status, showcasing its potential in significantly reducing liver fat in patients with advanced liver disease through cognitive behavioral therapy.

Prescription digital therapeutics (PDTs) are a rapidly growing area of healthcare. As a pharmacist, you should be aware of the potential benefits and risks of PDTs for your patients.

Explore the transformative potential of digital therapeutics (DTx) as the technologies team up with traditional therapeutics to reshape patient care.